Xemed

Executive Summary

Xemed is a private diagnostics company based in Durham, NC, founded in 2003, focused on developing hyperpolarized xenon-129 MRI contrast agents (MagniXene) for lung imaging. The technology leverages the distinct chemical shift of xenon to separate gas-phase and dissolved-phase signals, enabling detailed visualization of lung ventilation, gas exchange, and tissue perfusion. This approach has the potential to improve diagnosis and monitoring of chronic lung diseases such as COPD, asthma, and pulmonary fibrosis. Xemed's contrast agent is in preclinical or early clinical stages, with studies demonstrating feasibility in animal models. The company's niche in functional lung MRI could address a significant unmet need for non-invasive, radiation-free pulmonary imaging.

Upcoming Catalysts (preview)

• Q4 2026Publication of human clinical data for MagniXene in lung imaging60% success
• TBDFDA Investigational New Drug (IND) acceptance or breakthrough device designation45% success
• TBDStrategic partnership with a major imaging or pharmaceutical company for co-development35% success